Stock Research for ANIP

ANIP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ANIP Stock Chart & Research Data

The ANIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ANIP Due diligence Resources & Stock Charts

The ANIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANIP Detailed Price Forecast - CNN Money CNN View ANIP Detailed Summary - Google Finance
Yahoo View ANIP Detailed Summary - Yahoo! Finance Zacks View ANIP Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ANIP Trends & Analysis - Trade-Ideas Barrons View ANIP Major Holders - Barrons
NASDAQ View ANIP Call Transcripts - NASDAQ Seeking View ANIP Breaking News & Analysis - Seeking Alpha
Spotlight View ANIP Annual Report - CompanySpotlight.com OTC Report View ANIP OTC Short Report - OTCShortReport.com
TradeKing View ANIP Fundamentals - TradeKing Charts View ANIP SEC Filings - Bar Chart
WSJ View Historical Prices for ANIP - The WSJ Morningstar View Performance/Total Return for ANIP - Morningstar
MarketWatch View the Analyst Estimates for ANIP - MarketWatch CNBC View the Earnings History for ANIP - CNBC
StockMarketWatch View the ANIP Earnings - StockMarketWatch MacroAxis View ANIP Buy or Sell Recommendations - MacroAxis
Bullish View the ANIP Bullish Patterns - American Bulls Short Pains View ANIP Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ANIP Stock Mentions - StockTwits PennyStocks View ANIP Stock Mentions - PennyStockTweets
Twitter View ANIP Stock Mentions - Twitter Invest Hub View ANIP Investment Forum News - Investor Hub
Yahoo View ANIP Stock Mentions - Yahoo! Message Board Seeking Alpha View ANIP Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ANIP - SECform4.com Insider Cow View Insider Transactions for ANIP - Insider Cow
CNBC View ANIP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANIP - OTC Markets
Yahoo View Insider Transactions for ANIP - Yahoo! Finance NASDAQ View Institutional Holdings for ANIP - NASDAQ


Stock Charts

FinViz View ANIP Stock Insight & Charts - FinViz.com StockCharts View ANIP Investment Charts - StockCharts.com
BarChart View ANIP Stock Overview & Charts - BarChart Trading View View ANIP User Generated Charts - Trading View


Latest Financial News for ANIP

ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
Posted on Wednesday April 18, 2018

BAUDETTE, Minn., April 18, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application ("ANDA") for Morphine Sulfate Oral Solution 10mg/5mL, 20mg/5mL and 100mg/5mL. ANI expects to begin shipping product to its customers in the near future. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the approval of this internally developed generic product, which leverages both our liquid manufacturing and controlled substance capabilities.


ANI Acquires 23 ANDAs from IDT Australia, Ltd.
Posted on Wednesday April 04, 2018

BAUDETTE, Minn., April 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that it has acquired ANDAs for 23 previously marketed generic drug products from IDT Australia, Ltd. ("IDT") for $2.6 million and a limited single-digit royalty for one product. Additionally, ANI acquired active pharmaceutical ingredient for one of the acquired products for $135 thousand. In 2015, ANI had secured the U.S. licensing rights and 40% to 50% of the net profits upon commercialization for these products from IDT for $1.0 million. Today's acquisition gives ANI full control of the re-commercialization program and the vast majority of the economics for these products. Arthur S. Przybyl, President and CEO of ANI stated, "This acquisition advances our strategy of building a pipeline of previously approved generic drug products that can be re-commercialized via a CBE-30 (changes being effected in thirty days) or prior approval supplement filing.


Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?
Posted on Tuesday April 03, 2018

Investors are always looking for growth in small-cap stocks like ANI Pharmaceuticals Inc (NASDAQ:ANIP), with a market cap of US$678.34M. However, an important fact which most ignore is: how financiallyRead More...


Where ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its Industry
Posted on Thursday March 15, 2018

After looking at ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...


Enter a stock symbol to view the stock details.